Anti-NGF antibodies and uses thereof
AssigneeInvetx, Inc.
InventorsWilliam Brondyk, Jordan Willis, Leila Sevigny
Life of this patent
Estimating the term…
Abstract
The invention provides novel anti-NGF proteins, antibodies, and NGF-binding fragments thereof which inhibit association of NGF with TrkA and/or p75 and are suitable for administration to a canine or feline subject. The invention also provides novel compositions and methods of treating pain or eliciting an analgesic effect in a canine or feline subject, comprising administering an effective amount of an anti-NGF protein, antibody or fragment thereof. The methods and compositions are used to treat or prevent NGF-related disorders.
Claims30
An antigen binding protein that specifically binds to nerve growth factor (NGF), which comprises:
- a heavy chain variable domain (VH) which comprises:
- (a) a heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence X1X2X3X4TX6X7S (SEQ ID NO:378), wherein X1 comprises A or G, X2 comprises L or M, X3 comprises E or S, X4 comprises F or L, X6 comprises S or T, and X7 comprises H, N, or S;
- (b) a heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence IWSNX5GT (SEQ ID NO:379), wherein X5 comprises G or R;
- and
- (c) a heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence AX2IYYYX7ADYLHX13 YX15DX17 (SEQ ID NO:154) comprises, wherein X2 comprises N, Q, or S, X7 comprises D or E, X13 comprises F or W, X15 comprises F, I, L, W, or Y, and X17 comprises F, I, L, or M;
- and
- a light chain variable domain (VL) which comprises:
- (a) a light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence X1GIX4NX6 (SEQ ID NO:380), wherein X1 comprises D or E, X4 comprises Q or S, X6 comprises G, N, S or T;
- (b) a light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence ATX3 (SEQ ID NO:156), wherein X3 comprises D, E, N, Q, or S;
- and
- (c) a light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence QQGX4X5X6PLT (SEQ ID NO:157), wherein X4 comprises F, H, or Y, X5 comprises K or Q, and X6 comprises F or W.
Dependencies are inferred from the claim text.